Our custom analytic services provide access to cutting-edge systems developed for your specific needs. We can create systemic toxicology models with several interlinked organs, including: heart, liver, lung, brain, skin, muscle, GI tract, kidney, pancreas, endocrine, bone marrow and the neuromuscular junction. We can work with you to custom design your platform with almost any number of cell types in our patented serum-free system.
The difference in solubility between oxygen and carbon dioxide in the cells’ medium can cause gas bubbles to accumulate over time, disrupting the system’s tightly controlled fluid flows and causing a problem during extended metabolic testing. Our models use a serum-free cell medium and a carefully designed gravity flow system to eliminate the need for pumps.
functional cardiac module
The Cardiac Analytic Service provides unique physiological functional monitoring of the status of human cells living within a pump-less system for both function generation & electrical parameters including QT interval. To learn more - refer to the following publication here
The quest for cures for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy hinges on the ability of scientists to test treatments. Our pioneering model of the neuromuscular junction realistically recreates the physiology of motoneuron signaling and enables interconnected as well as isolated treatment of motoneurons and muscle. Refer to our latest publication here.
blood brain barrier (BBB)
We developed a microfluidic BBB model that is capable of mimicking in vivo BBB characteristics for a prolonged period and allows for reliable in vitro drug permeability studies under recirculating perfusion. Our BBB‐on‐a‐chip model closely mimics physiological BBB barrier functions and is a valuable tool for screening of drug candidates. The residence time‐based design of a microfluidic platform enables integration with other organ modules to simulate multi‐organ interactions on drug response. Our analyses demonstrated that the permeability coefficients measured using our model were comparable to in vivo values. Read the full publication here.
Predicting drug-induced liver injury with in vitro cell culture models more accurately would be of significant value to the pharmaceutical industry. To this end we have developed a low-cost liver cell culture device that creates fluidic flow over a 3D primary liver cell culture that consists of multiple liver cell types, including hepatocytes and non-parenchymal cells (fibroblasts, stellate cells, and Kupffer cells). Our results indicate that device operation with bi-directional gravity-driven medium flow supports the 14-day culture of a mix of primary human liver cells with the benefits of enhanced metabolic activity. Our mode of device operation allows us to evaluate drugs under fluidic cell culture conditions and at low device
manufacturing and operation costs.
human skin equivalent (HSE)
In this study published in Lab Chip, we designed and developed a microfluidic platform that allows for long-term maintenance of full thickness human skin equivalents (HSE) which are comprised of both the epidermal and dermal compartments. The design is based on the physiologically relevant blood residence times in human skin tissue and allows for the establishment of an air-epidermal interface which is crucial for maturation and terminal differentiation of HSEs. The small scale of the design reduces the amount of culture medium and the number of cells required by 36 fold compared to conventional transwell cultures.Overall, the HSE-on-a-chip is a user-friendly and cost-effective in vitro platform for drug testing of candidate molecules for skin disorders.